ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
Explore this paper's citation graph
Summary
The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the post-approval clinical setting.
- Type
- review
- Published
- 2018-12-25
- Cited by
- 3,195
- References
- 40
- Access
- Open access
- OpenAlex
- https://openalex.org/W2905654445
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:58664454
Keywords
Medicine, Effector, Grading (engineering), Immune system, Toxicity
References
- Reference Range for Cerebrospinal Fluid Opening Pressure in Children
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
- Current concepts in the diagnosis and management of cytokine release syndrome.
- Swelling of the optic nerve head: a staging scheme
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- Delirium screening anchored in child development: The Cornell Assessment for Pediatric Delirium
- Cornell Assessment of Pediatric Delirium: A Valid, Rapid, Observational Tool for Screening Delirium in the PICU
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia
- CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
- Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
- Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
Cited by
- G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
- Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy
- Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
- Anti-CD19 CAR T cell therapy for lymphoma — off to the races!
- Toxicities of CD19 CAR‐T cell immunotherapy
- Early and late hematologic toxicity following CD19 CAR-T cells
- Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy
- Driving CAR T cell translation forward
- Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
- Mechanisms of resistance to CAR T cell therapy
- Comments Regarding "ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells".
- Associated Toxicities: Assessment and management related to CAR T‐cell therapy
- Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma
- Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
- In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
- CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm
- CAR T Cell Toxicity: Current Management and Future Directions
- NextGen cell-based immunotherapies in cancer and other immune disorders.
- Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car.
Related papers
- Crucial Roles of Effectors in Interactions between Horticultural Crops and Pathogens
- Prediction of effector proteins and their implications in pathogenicity of phytopathogenic filamentous fungi: A review.
- Remote homology clustering identifies lowly conserved families of effector proteins in plant-pathogenic fungi
- Fungal Effectoromics: A World in Constant Evolution
- "Order from disordered": Potential role of intrinsically disordered regions in phytopathogenic oomycete intracellular effector proteins.
- Cytokine release syndrome
- Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome
- Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)